Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · December 26, 2013

Increased pCR With Addition of Capecitabine to Epirubicin/Docetaxel in Neoadjuvant Treatment of Breast Cancer

Annals of Oncology

 

Additional Info

Annals of Oncology
Epirubicin and Docetaxel With or Without Capecitabine as Neoadjuvant Treatment for Early Breast Cancer: Final Results of a Randomized Phase III Study (ABCSG-24)
Ann. Oncol 2013 Dec 16;[EPub Ahead of Print], GG Steger, R Greil, A Lang, M Rudas, F Fitzal, B Mlineritsch, BL Hartmann, R Bartsch, E Melbinger, M Hubalek, H Stoeger, P Dubsky, S Ressler, AL Petzer, CF Singer, C Muss, R Jakesz, SP Gampenrieder, CC Zielinski, C Fesl, M Gnant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading